With advancements in targeted therapies, the combination of BRAF and MEK inhibitors has demonstrated prolonged survival and delayed resistance in patients with BRAF mutations, while immune checkpoint inhibitors have shown effectiveness across both BRAF-mutant and wild-type melanoma cases. The gene discussed is BRAF; the disease is melanoma.